Table 4.

Current HSCT clinical trial approaches in myelofibrosis

Current HSCT clinical trial approaches in myelofibrosis

Flu indicates fludarabine; Mel, melphalan; ATG, anti-thymocyte globulin; Bu, busulfan; PFS, progression free survival; DFS, disease free survival; NRM, non-relapse mortality; MRD, matched/mismatched related donor; MUD, matched/mismatched unrelated donor; CB, cord blood; and TBD, to be determined.

Close Modal

or Create an Account

Close Modal
Close Modal